ALSO NOTED: Texas lawmakers reject HPV deal; New warnings on sleep drugs; and much more...

> The Texas House handed the state governor a lopsided defeat yesterday, rejecting his order that required HPV vaccines as a condition for school attendance. Report

> The FDA is demanding drug makers to add new warnings to sleep drugs to alert users about two rare but dangerous side effects: sleep-driving and severe allergic reactions. Report

> Prima BioMed announced that a small Phase IIa trial for its ovarian cancer therapy "exceeded expectations." Four of 21 patients in the study had either a positive response or saw the disease stabilize, exceeding the 15 percent response rate that researchers had set as a goal. Report

> Optimer Pharmaceuticals reported that the FDA has agreed with the recommendation of the independent data safety monitoring board to advance Difimicin (OPT-80/PAR101) into Phase III clinical studies. Release

> India's Syngene International has inked an R&D and early drug development agreement with Bristol-Myers Squibb. No terms were disclosed. Report

> Advanced Life Sciences Holdings anthrax inhalation therapy cethromycin has received orphan drug status. Report

> The FDA has given Avigen the green light to commence Phase II clinical development of AV650 (tolperisone). Release

And Finally… A new study projects a looming shortage of cancer doctors as demand for their services soars. Article

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.